Copyright © 2001 by the European Society of Cardiology.
The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound
a Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
b Heartcenter Bodensee, Kreuzlingen, Switzerland
c Cardialysis, Rotterdam, The Netherlands
revised January 29, 2001; accepted January 31, 2001
Abstract
Background Studies have reported benefit of oral therapy with the phosphodiesterase inhibitor, trapidil, in reducing restenosis after coronary angioplasty. Coronary stenting is associated with improved late outcome compared with balloon angioplasty, but significant neointimal hyperplasia still occurs in a considerable proportion of patients. The aim of this study was to investigate the safety and efficacy of trapidil 200mg in preventing in-stent restenosis.
Methods Patients with a single native coronary lesion requiring revascularization were randomized to placebo or trapidil at least 1h before, and continuing for 6 months after, successful implantation of a coronary Wallstent. The primary end-point was in-stent neointimal volume measured by three-dimensional reconstruction of intravascular ultrasound images recorded at the 6 month follow-up catheterization.
Results Of 312 patients randomized at 21 centres in nine countries, 303 (148 trapidil, 155 placebo) underwent successful Wallstent implantation, and 139 patients (90%) in the placebo group and 130 (88%) in the trapidil group had repeat catheterization at 26±2 weeks. There was no significant difference between trapidil and placebo-treated patients regarding in-stent neointimal volume (108·6± 95·6mm3vs 93·3±79·1mm3;P=0·16) or % obstruction volume (38±18% vs 36±21%;P=0·32), in angiographic minimal luminal diameter at follow-up (1·63±0·61mm vs 1·74±0·69mm;P=0·17), restenosis rate (31% vs 24%;P=0·24), cumulative incidence of major adverse cardiac events at 7 months (22% vs 20%;P=0·71) or anginal complaints (30% vs 24%;P=0·29).
Conclusion Oral trapidil 600mg daily for 6 months did not reduce in-stent hyperplasia or improve clinical outcome after successful Wallstent implantation and is not indicated for this purpose.
Key Words: Restenosis, stent, trapidil, intravascular ultrasound, quantitative coronary angiography, randomized trial
f1 Correspondence:Prof. P. W. Serruys, Erasmus Medical Center, Thoraxcenter Bd 408, Dr.Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
References
- Serruys PW, de Jaegere P, Kiemeneij F. A comparison of Balloon-expandable -stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489–495
[Abstract/Free Full Text] - Fischman DL, Leon MB, Baim DS. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501
[Abstract/Free Full Text] - Foley DP, Rensing BJ, Pieper M. Clinical and quantitative angiographic outcomes following elective implantation of the self-expanding Wallstent for longer coronary artery lesions-Final results of the Wellstent Native study. Int J Cardiovasc Interv. 1999;2:171–179[Medline]
- Cercek B, Ebrahimi R, Dimayuga P, Khorsandi M, Forrester JS. Trapidil prevents rat smooth muscle cell proliferation in vitro and in vivo. J Am Coll Cardiol. 1991;17:72A
- Liu MW, Roubin GS, Robinson KA. Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation. 1990;81:1089–1093
[Abstract/Free Full Text] - Okamoto S, Inden M, Setsuda M, Konishi T, Nakano T. Effects of Trapidil a platelet derived growth factor antagonist, in preventing restenosis after percutaneous transcoronary angioplasty. Am Heart J. 1992;123:1439–1444[CrossRef][ISI][Medline]
- Maresta A, Balducelli M, Cantini L. Trapidil, a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty; results of the randomized, double-blind STARC Study. Circulation. 1994;90:2710–2715
[Abstract/Free Full Text] - Wittpoth M, Bönisch D, Schrör K. Trapidil inhibits RAF-1 kinase in vascular smooth muscle cells via activation of protein kinase A (PKA). Circulation. 1997;96:I-558
- Isner JM. Vascular remodelling. Honey, I think I shrunk the artery. Circulation. 1994;89:2837–2941
- Circulation. 1999;100:799–806
[Abstract/Free Full Text] - De Feyter PJ, Kay P, Disco C, Serruys PW. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative angiography. Circulation. 1999;100:1777–1783
[Abstract/Free Full Text] - Li W, von Birgelen C, Hartlooper A. Semi-automated contour detection for volumetric quantification of intracoronary ultrasound. Computers in Cardiology. Washington: IEEE Computer Society Press; 1994. p. 277–80
- Von Birgelen C, Di Mario C, Li W, Schuurbiers JC. Morphometric analysis in three-dimensional intracoronary ultrasound an in vivo and in vitro study performed with a novel system for contour detection of lumen and plaque. Am Heart J. 1996;132:516–527[CrossRef][ISI][Medline]
- Von Birgelen C, Airiian SG, de Feyter PJ, Foley DP, van der Giessen WJ, Serruys PW. Coronary Wallstents show significant late, post-procedural expansion despite implantation with adjunct high-pressure balloon inflatation. Am J Cardiol. 1996;132:694–696
- Harder S, Thürmann P, Hellstern A, Benjaminov A. Pharmacokinetics of trapidil, an antagonist of platelet derived growth factor, in healthy subjects and in patients with liver chirrosis. Br J Clin Pharmacol. 1996;42:443–449[CrossRef][ISI][Medline]
- Serruys PW, Foley DP, de Feyter PJ. Quantitative coronary angiography in clinical practice. Dordrecht/Boston/London: Kluwer Academic Publishers; 1994.
- Ohnishi H, Yamaguchi K, Shimada S, Suzucki Y, Kumagai A. A new approach to treatment of atherosclerosis and Trapidil as an antagonist to platelet-derived growth factor. Life Sci. 1982;31:2595–2602[CrossRef][ISI][Medline]
- Tiell ML, Sussmann I, Gordon PB, Sanders RN. Suppression of fibroblast proliferation in vitro and of neointimal hyperplasia in vivo by the triazolopyrimidine, Trapidil. Artery. 1983;12:33–50[ISI][Medline]
- Bönisch D, Weber AA, Withpoth M, Osinski M, Schrör K. Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A. Mol Pharmacol. 1998;54:241–248
[Abstract/Free Full Text] - Galassi AR, Tamburino C, Nicosia A. A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation. Catheter Cardiovasc Interv. 1999;46:162–168[CrossRef][ISI][Medline]
- Ozaki Y, Keane D, Ruygrok P, vd Giessen WG, de Feyter P, Serruys PW. Six month clinical and angiographic outcome of the new less-shortening Wallstent in native coronary arteries. Circulation. 1996;93:2114–2120
[Abstract/Free Full Text] - Hanke H, Kamenz J, Hassenstein S. Prolonged proliferative response of smooth muscle cells after experimental intravascular stenting. Eur Heart J. 1995;16:785–793
[Abstract/Free Full Text] - Sabate M, Marijnissen JP, Carlier SG. Residual plaque burden, delivered dose, and tissue composition predict 6-month outcome after balloon angioplasty and beta-radiation therapy. Circulation. 2000;101:2472–2477
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. J. Lansky, R. A. Costa, G. S. Mintz, Y. Tsuchiya, M. Midei, D. A. Cox, C. O'Shaughnessy, R. A. Applegate, L. A. Cannon, M. Mooney, et al. Non-Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial Circulation, April 27, 2004; 109(16): 1948 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. E.J. West, P. N. Ruygrok, C. M.C. Disco, M. W.I. Webster, W. K. Lindeboom, W. W. O'Neill, N. F. Mercado, and P. W. Serruys Clinical and Angiographic Predictors of Restenosis After Stent Deployment in Diabetic Patients Circulation, February 24, 2004; 109(7): 867 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Serruys, M. Degertekin, K. Tanabe, M. E. Russell, G. Guagliumi, J. Webb, J. Hamburger, W. Rutsch, C. Kaiser, R. Whitbourn, et al. Vascular Responses at Proximal and Distal Edges of Paclitaxel-Eluting Stents: Serial Intravascular Ultrasound Analysis From the TAXUS II Trial Circulation, February 10, 2004; 109(5): 627 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Mercado, W Maier, E Boersma, C Bucher, V de Valk, W.W O'Neill, B.J Gersh, B Meier, P.W Serruys, and W Wijns Clinical and angiographic outcome of patients with mild coronary lesions treated with balloon angioplasty or coronary stenting: Implications for mechanical plaque sealing Eur. Heart J., March 2, 2003; 24(6): 541 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Babapulle and M. J. Eisenberg Coated Stents for the Prevention of Restenosis: Part I Circulation, November 19, 2002; 106(21): 2734 - 2740. [Full Text] [PDF]
|
|
|
|
|
|
M. Degertekin, P. W. Serruys, D. P. Foley, K. Tanabe, E. Regar, J. Vos, P. C. Smits, W. J. van der Giessen, M. van den Brand, P. de Feyter, et al. Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up Circulation, September 24, 2002; 106(13): 1610 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.G. Murphy A monk's prayer: O Lord what is the answer to in-stent restenosis? Commentary on the TRAPIST Study Eur. Heart J., October 2, 2001; 22(20): 1847 - 1849. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||